Trump Administration Files Fraud Charges Against Southern Poverty Law Center Over Informant Payments 
Comey Faces Charges Over Instagram Post as Free Speech Debate Intensifies 
Asian Stocks Rise Despite Middle East Tensions as Chipmakers Boost Markets 
NASA Resumes Cygnus XL Cargo Docking with Space Station After Software Fix 
Judge Rules Use of Military Lawyers in Civilian Prosecutions Is Lawful 
Trump Administration Seeks Court Pause to Reinstate 10% Global Tariffs 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
Trump DOJ Challenges Colorado’s Large-Capacity Magazine Ban in Second Amendment Lawsuit 
South Korea Central Bank Signals Inflation Concerns as Oil Prices Surge 
Trump Says Iran Ceasefire ‘On Life Support’ as Oil Prices Surge Above $104 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Goldman Sachs Delays Fed Rate Cut Forecast to 2026 Amid Rising Inflation Concerns 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
The Seoul Central District Court had ruled that Medytox's patents for botulinum toxin (botox) strains and manufacturing process were stolen by Daewoong Pharmaceutical in developing Nabota.
Thus, the court prohibited Daewoong from manufacturing and selling its botox products, ordering that those that have already been produced should be discarded.
It also ordered Daewoong to pay 40 billion won in damages to Medytox, the first Korean company to succeed in mass-producing botox strains.
Medytox sued Daewoong in 2017, accusing it of stealing its botox strain and manufacturing process.
Daewoong claimed that it found its botox strain in a barn in Gyeonggi Province.
Medytox vowed to continue to protect its patent, while Daewoong said it would appeal the ruling.
The US International Trade Commission (USITC) had earlier ruled in favor of Medytox in December 2020 and ordered a 21-month import ban on Daewoong's products into the US. Daewoong also agreed to pay royalties to Medytox to settle the dispute shortly after the USITC decision.
